The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
This inspection was conducted following the warning letter issued by the USFDA
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Ultra-high purity surfactant for biologics and parenteral drug formulations
The facility has been classified as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated